Elsevier

Biochemical Pharmacology

Volume 84, Issue 9, 1 November 2012, Pages 1196-1206
Biochemical Pharmacology

Metabolic activation by human arylacetamide deacetylase, CYP2E1, and CYP1A2 causes phenacetin-induced methemoglobinemia

https://doi.org/10.1016/j.bcp.2012.08.015Get rights and content

Abstract

Phenacetin has been used as an analgesic antipyretic but has now been withdrawn from the market due to adverse effects such as methemoglobinemia and renal failure. It has been suggested that metabolic activation causes these adverse effects; yet, the precise mechanisms remain unknown. We previously demonstrated that human arylacetamide deacetylase (AADAC) was the principal enzyme catalyzing the hydrolysis of phenacetin. In this study, we assessed whether AADAC was involved in phenacetin-induced methemoglobinemia. A high methemoglobin (Met-Hb) level in the blood was detected 1 h after administration of phenacetin (250 mg/kg, p.o.) to male C57BL/6 mice. Pre-administration of tri-o-tolylphosphate, a general esterase inhibitor, was found to decrease the levels of Met-Hb and the plasma concentration of p-phenetidine, a hydrolyzed metabolite of phenacetin. An in vitro study using red blood cells revealed that incubation of phenacetin or p-phenetidine with human liver microsomes (HLM) increased the formation of Met-Hb. To identify the enzymes involved in the formation of Met-Hb, we used recombinant enzymes and HLM treated with inhibitors in the measurement of the formation of Met-Hb. High levels of Met-Hb were observed following incubation of human AADAC with either cytochrome P450 (CYP) 1A2 or CYP2E1. Furthermore, the increased Met-Hb formation by the incubation of HLM with phenacetin was significantly inhibited to 25.1 ± 0.7% of control by eserine, a potent AADAC inhibitor. In conclusion, we found that the hydrolysis by AADAC and subsequent metabolism by CYP1A2 and CYP2E1 play predominant roles in phenacetin-induced methemoglobinemia.

Introduction

Phenacetin has been widely used as an analgesic antipyretic. Although phenacetin had been developed as a prodrug of acetaminophen (APAP), it was withdrawn from the market as it caused methemoglobinemia and renal failure [1], [2]. Phenacetin is primarily metabolized to APAP through O-deethylation by human cytochrome (CYP) 1A2 as well as partially by CYP2E1 and is also metabolized to p-phenetidine through a hydrolysis reaction [3], [4], [5]. p-Phenetidine is considered to be further metabolized to N-hydroxy-p-phenetidine, a metabolite thought to contribute adverse effects [1], [6].

Methemoglobin (Met-Hb) is formed when the iron of hemoglobin is oxidized from the ferrous (Fe2+) to the ferric state (Fe3+). Met-Hb cannot bind and transport oxygen; consequently, the increased levels of Met-Hb are associated with clinically severe symptoms [7]. The normal level of Met-Hb is 1.5–2% of the total hemoglobin. As the Met-Hb level rises above 10% of the total hemoglobin levels, cyanosis usually develops. This is followed by anxiety, fatigue, and tachycardia at Met-Hb levels between 20% and 50%. Finally, under conditions of Met-Hb levels exceeding 50–70% of the total hemoglobin, coma and death may occur [8].

The metabolic pathway of phenacetin hydrolysis and subsequent metabolism is thought to contribute to phenacetin-induced methemoglobinemia. However, this involvement has not been experimentally shown. Contributing to this paucity in experimental evidence is the fact that the enzymes responsible for phenacetin-induced methemoglobinemia have not been identified. Previously, we have shown that human arylacetamide deacetylase (AADAC) is the principal enzyme catalyzing the hydrolysis of phenacetin [9]. AADAC is one of the major serine esterases expressed in human liver and the gastrointestinal tract [10]. AADAC is capable of hydrolyzing the antiandrogen drug flutamide, the antituberculosis drug rifampicin [10], [11], and phenacetin. Nakayama and Masuda reported that an NADPH-dependent enzyme(s) is associated with an increase in the formation of Met-Hb formation induced by p-phenetidine [12]. Therefore, representative NADPH-dependent enzymes such as the CYP enzymes may play an important role in the metabolism of p-phenetidine and formation of Met-Hb. CYP enzymes are widely involved in drug metabolism (approximately 75% of all clinically used drugs) and are sometimes involved in the development of toxicity. Building on this background information, we investigated with in vivo and in vitro studies whether AADAC and CYP enzymes are responsible for phenacetin hydrolysis and the subsequent metabolism, respectively, resulting in phenacetin-induced methemoglobinemia.

Section snippets

Chemicals and reagents

APAP, phenacetin, potassium cyanide, potassium hexacyanoferrate (III), p-nitrophenol, and eserine were purchased from Wako Pure Chemical Industries (Osaka, Japan). p-Phenetidine, p-nitrophenyl acetate (PNPA), chlorzoxazone, 6-hydroxychlorzoxazone, and bis-(p-nitrophenyl)phosphate (BNPP) were obtained from Sigma–Aldrich (St. Louis, MO). Tri-o-tolyl phosphate (TOTP) was obtained from Kanto Chemical (Tokyo, Japan). Human liver microsomes (HLM) (pooled donors, n = 50), recombinant human CYP1A2,

Changes of Met-Hb levels upon phenacetin administration in mice and plasma concentrations of phenacetin and its metabolites

After administration of phenacetin (250 mg/kg, p.o.) to male C57BL/6 mice, the levels of Met-Hb and the plasma concentrations of phenacetin, p-phenetidine, and APAP were measured at various time points over 0–6 h (Fig. 1). In preliminary work, we could detect the formation of Met-Hb 1 h after the administration of either 250 mg/kg or 500 mg/kg phenacetin (16.7 ± 2.1% and 32.3 ± 3.5%, respectively), but not following the administration of 100 mg/kg phenacetin (1.7 ± 0.6%). Because high levels of Met-Hb

Discussion

Phenacetin, an analgesic antipyretic, was withdrawn from the market because it caused methemoglobinemia and renal failure [1], [2]. It was suggested that phenacetin-induced methemoglobinemia was associated with hydrolysis and subsequent N-hydroxylation of phenacetin [1], [22]. Previously, our studies showed that AADAC was the principal enzyme catalyzing the hydrolysis of phenacetin [9]. However, it has not been experimentally shown which enzymes play essential roles in phenacetin-induced

Acknowledgement

The Japan Society for the Promotion of Science supported this study [Grant-in-Aid for Young Scientists (B) 21790148].

References (38)

  • K.G. Eckert et al.

    Differences in the reactions of isomeric ortho- and para-aminophenols with hemoglobin

    Biochem Pharmacol

    (1983)
  • C.C. Winterbourn et al.

    Superoxide dismutase as an inhibitor of reactions of semiquinone radicals

    FEBS Lett

    (1978)
  • A.M. Khan et al.

    Flutamide induced methemoglobinemia

    J Urol

    (1997)
  • M. Gago-Dominguez et al.

    Regular use of analgesics is a risk factor for renal cell carcinoma

    Br J Cancer

    (1999)
  • M.A. Butler et al.

    Human cytochrome P-450PA (P-450IA2), the phenacetin O-deethylase, is primarily responsible for the hepatic 3-demethylation of caffeine and N-oxidation of carcinogenic arylamines

    Proc Natl Acad Sci USA

    (1989)
  • K. Kobayashi et al.

    Involvement of CYP2E1 as a low-affinity enzyme in phenacetin O-deethylation in human liver microsomes

    Drug Metab Dispos

    (1999)
  • S. Kudo et al.

    Phenacetin deacetylase activity in human liver microsomes: distribution, kinetics, and chemical inhibition and stimulation

    J Pharmacol Exp Ther

    (2000)
  • P.J. Wirth et al.

    Mutagenicity of N-hydroxy-2-acetylaminofluorene and N-hydroxy-phenacetin and their respective deacetylated metabolites in nitroreductase deficient Salmonella TA98FR and TA100FR

    Carcinogenesis

    (1982)
  • T.J. Moore et al.

    Reported adverse event cases of methemoglobinemia associated with benzocaine products

    Arch Intern Med

    (2004)
  • Cited by (17)

    • Epicatechin gallate and epigallocatechin gallate are potent inhibitors of human arylacetamide deacetylase

      2021, Drug Metabolism and Pharmacokinetics
      Citation Excerpt :

      The formation of reactive metabolites as a result of drug metabolism is also known to cause side effects, with P450s receiving great attention. Recently, we demonstrated that drug metabolism by CES1, CES2, and AADAC can cause side effects as a result of the production of reactive metabolites [5,11–14]. For example, the metabolic reactions catalyzed by CES1 and/or CES2 are involved in prilocaine- and lidocaine-induced methemoglobinemia [12], whereas the hydrolysis of phenacetin and ketoconazole by AADAC has been linked with methemoglobinemia and hepatotoxicity, respectively [5,14].

    • A proposed mechanism for the adverse effects of acebutolol: CES2 and CYP2C19-mediated metabolism and antinuclear antibody production

      2015, Biochemical Pharmacology
      Citation Excerpt :

      PMSF, BNPP, and DFP showed potent inhibition of CES1 and CES2 [24,33], but 100 μM PMSF did not inhibit AADAC [21,34]. Eserine showed potent inhibition of CES2 and AADAC [9]. Digitonin inhibited CES1.

    • A comprehensive review of UDP-glucuronosyltransferase and esterases for drug development

      2015, Drug Metabolism and Pharmacokinetics
      Citation Excerpt :

      However, preincubation with the inhibitors for 1 h increases the inhibitory effects of rivastigmine (strong inhibition for both CES1 and CES2) and tacrine (moderate inhibition for CES2 only) [272]. Notably, eserine potently inhibits CES2 and AADAC [256]. Therefore, the choice of cholinesterase inhibitor in an inhibition study is important.

    View all citing articles on Scopus
    View full text